Biocryst Pharmaceuticals (BCRX) Total Debt (2011 - 2026)

Biocryst Pharmaceuticals' Total Debt history runs 16 years deep, the most recent figure standing at $435.5 million for Q1 2026.

• Quarterly Total Debt rose 24.53% year-over-year to $435.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $435.5 million (up 24.53% YoY) and the FY2025 annual result came in at $38.5 million, down 88.94% from the prior year.
• Total Debt was $435.5 million for Q1 2026 at Biocryst Pharmaceuticals, up from $38.5 million in the prior quarter.
• Across five years, Total Debt topped out at $435.5 million in Q1 2026 and bottomed at $38.5 million in Q4 2025.
• A 5-year average of $270.4 million and a median of $293.2 million in 2023 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2023 — Total Debt soared 102.87% — and 2025, when it plunged 88.94%.
• Biocryst Pharmaceuticals' Total Debt stood at $231.6 million in 2022, then jumped by 41.09% to $326.8 million in 2023, then increased by 6.35% to $347.5 million in 2024, then plunged by 88.94% to $38.5 million in 2025, then jumped by 1032.53% to $435.5 million in 2026.
• Business Quant data shows BCRX's Total Debt at $435.5 million in Q1 2026, $38.5 million in Q4 2025, and $232.1 million in Q3 2025.